Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Larisa V. Gubareva"'
Autor:
Krista Kniss, Juan A. De La Cruz, Anton Chesnokov, Larisa V. Gubareva, Angiezel Merced-Morales, Jennifer Laplante, Kirsten St. George, David E. Wentworth, Rebecca Kondor, Teena Mohan, Ha T. Nguyen, Vasiliy P. Mishin, Patricia A. Blevins
Publikováno v:
Emerging Infectious Diseases, Vol 27, Iss 7, Pp 1953-1957 (2021)
Emerging Infectious Diseases
Emerging Infectious Diseases
Four cases of oseltamivir-resistant influenza A(H1N1)pdm09 virus infection were detected among inhabitants of a border detention center in Texas, USA. Hemagglutinin of these viruses belongs to 6B.1A5A-156K subclade, which may enable viral escape from
Autor:
Jackie Katz, Rebecca Garten, Anton Chesnokov, Vasiliy P. Mishin, Heather Reid, John Barnes, Angela P Campbell, Mira C. Patel, Ha T. Nguyen, Sarah Spencer, Larisa V. Gubareva, Juan A. De La Cruz, Mallory Sinner, David E. Wentworth, Alicia M. Fry
Publikováno v:
Eurosurveillance
The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one
Autor:
K.J. Spackman, Margaret Okomo-Adhiambo, Morra Carlos, B. Healey, Larisa V. Gubareva, M. Mendenhall, Xiyan Xu, Stephanie Chester, Jennifer Laplante, T. Aden, Vasiliy P. Mishin, Richard H. Griesser, H. Guevara, Erik Reisdorf, Katrina Sleeman, E. Saguar, K. St George
Publikováno v:
Antiviral Research. 128:28-35
Background Monitoring influenza virus susceptibility to neuraminidase (NA) inhibitors (NAIs) is vital for detecting drug-resistant variants, and is primarily assessed using NA inhibition (NI) assays, supplemented by NA sequence analysis. However, dif
Autor:
Margaret, Okomo-Adhiambo, Alicia M, Fry, Su, Su, Ha T, Nguyen, Anwar Abd, Elal, Elizabeth, Negron, Julie, Hand, Rebecca J, Garten, John, Barnes, Xu, Xiyan, Julie M, Villanueva, Larisa V, Gubareva, Reginald, McClinton
Publikováno v:
Emerging Infectious Diseases, Vol 21, Iss 1, Pp 136-141 (2015)
Emerging Infectious Diseases
Emerging Infectious Diseases
We report characteristics of oseltamivir-resistant influenza A(H1N1)pdm09 viruses and patients infected with these viruses in the United States. During 2013–14, fifty-nine (1.2%) of 4,968 analyzed US influenza A(H1N1)pdm09 viruses had the H275Y ose
Autor:
Larisa V. Gubareva, Katrina Sleeman, Amanda Balish, Vasiliy P. Mishin, Rebecca Garten, Alicia M. Fry, Julie Villanueva, Zhu Guo, James Stevens
Publikováno v:
Antimicrobial Agents and Chemotherapy. 58:2045-2051
Since 2011, outbreaks caused by influenza A(H3N2) variant [A(H3N2)v] viruses have become a public health concern in the United States. The A(H3N2)v viruses share the A(H1N1)pdm09 M gene containing the marker of M2 blocker resistance, S31N, but do not
Autor:
Larisa V. Gubareva, Katrina Sleeman, Zack Moore, Alicia M. Fry, Susan Kilpatrick, Shikha Garg, Tiffany G. Sheu
Publikováno v:
Emerging Infectious Diseases, Vol 17, Iss 11, Pp 2043-2046 (2011)
Emerging Infectious Diseases
Emerging Infectious Diseases
Oseltamivir is 1 of 2 antiviral medications available for the treatment of influenza B virus infections. We describe and characterize a cluster of influenza B viruses circulating in North Carolina with a mutation in the neuraminidase active site that
Autor:
Margaret Okomo-Adhiambo, Larisa V. Gubareva, Katrina Sleeman, Anwar Isa Abd Elal, Ha T. Nguyen, Alicia M. Fry
Publikováno v:
Influenza and Other Respiratory Viruses
Background Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpret
Autor:
Chao Yang Pan, Saumil Doshi, Laurie Kamimoto, Christine L. Waters, Larisa V. Gubareva, Margaret Okomo-Adhiambo, Kirsten St. George, Samuel B. Graitcer, Alexander Klimov, Zack Moore, Alicia M. Fry, Steven A. Marshall, Meredith Vandermeer, Jennifer Laplante, Janice K. Louie, Katrina Sleeman
Publikováno v:
Emerging Infectious Diseases
Emerging Infectious Diseases, Vol 17, Iss 2, Pp 255-257 (2011)
Emerging Infectious Diseases, Vol 17, Iss 2, Pp 255-257 (2011)
During April 2009–June 2010, thirty-seven (0.5%) of 6,740 pandemic (H1N1) 2009 viruses submitted to a US surveillance system were oseltamivir resistant. Most patients with oseltamivir-resistant infections were severely immunocompromised (76%) and h